# OnCo record paper-rizvi-targeted-ngs-immunotherapy-determinants-jco-2018 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-rizvi-targeted-ngs-immunotherapy-determinants-jco-2018/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-rizvi-targeted-ngs-immunotherapy-determinants-jco-2018" ;
  schema:name "Molecular determinants of response to anti-PD-1 and anti-PD-L1 blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing"@en ;
  schema:description "The routine gene panel used in clinic can estimate how many mutations a lung cancer carries almost as well as sequencing the whole exome can, and tumours with more mutations were more likely to benefit from immunotherapy, independently of the PD-L1 stain."@en ;
  schema:url <https://onco.cc/key-papers/paper-rizvi-targeted-ngs-immunotherapy-determinants-jco-2018/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://doi.org/10.1200/JCO.2017.75.3384>, <https://pubmed.ncbi.nlm.nih.gov/29337640/>, <https://www.cbioportal.org/study/summary?id=nsclc_pd1_msk_2018> ;
  schema:sameAs <https://doi.org/10.1200/JCO.2017.75.3384> ;
  schema:datePublished "2018"^^xsd:gYear ;
  schema:author "Rizvi H, Sanchez-Vega F, La K, et al." ;
  onco:related <https://onco.cc/biomarkers/tmb-high/>, <https://onco.cc/biomarkers/pd-l1-tps/> ;
  onco:cancers <https://onco.cc/cancers/nsclc/> ;
  onco:technologies <https://onco.cc/technologies/cgp/>, <https://onco.cc/technologies/tmb-testing/>, <https://onco.cc/technologies/wes-wgs/>, <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/pdl1/>, <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/egfr/>, <https://onco.cc/targets/stk11/> ;
  onco:institutions <https://onco.cc/institutions/mskcc/> ;
  onco:pathways <https://onco.cc/pathways/cancer-immunity-cycle/>, <https://onco.cc/pathways/pd1-checkpoint/> ;
  onco:terms <https://onco.cc/terms/tmb/>, <https://onco.cc/terms/ngs/>, <https://onco.cc/terms/neoantigen/>, <https://onco.cc/terms/stk11-keap1/> ;
  onco:people <https://onco.cc/people/matthew-hellmann/> ;
  onco:journals <https://onco.cc/journals/jco/> .
